

REFERENCES

1. Kinoshita S., Inoue Y., Nakama S., Ichiba T., Aniya Y. Antioxidant and hepatoprotective actions of medicinal herb, *Terminalia catappa* L. from Okinawa Island and its tannin corilagin. *Phytomedicine*. 2007;14(11):755-62.
2. Braga FC., Serra CP., Viana Júnior NS., Oliveira AB., Côrtes SF., Lombardi JA. Angiotensin-converting enzyme inhibition by Brazilian plants. *Fitoterapia*. 2007;78(5):353-8.
3. Ahmed SM., Swamy V., Gopkumar P., Dhanapal R. Anti-diabetic activity of *Terminalia catappa* Linn. leaf extracts in alloxan-induced diabetic rats. *Iranian J Pharmacol and Therapeutics*. 2005;4(1):36--9.
4. Goun E., Cunningham G., Chu D., Nguyen C., Miles D. Antibacterial and antifungal activity of Indonesian ethnomedical plants. *Fitoterapia*. 2003;74(6):592-6.
5. Tan G., Pezzuto J., Kinghorn A., Hughes S. Evaluation of natural products as inhibitors of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase. *J Nat Prod*. 1991;54(1):143-54.
6. Chu S-C., Yang S-F., Liu S-J., Kuo W-H., Chang Y-Z., Hsieh Y-S.. *In vitro* and *in vivo* antimetastatic effects of *Terminalia catappa* L. leaves on lung cancer cells. *Food Chem Toxicol*. 2007;45(7):1194-201.
7. Fan YM., Xu LZ., Gao J., Wang Y., Tang XH., Zhao XN., et al. Phytochemical and antiinflammatory studies on *Terminalia catappa*. *Fitoterapia*. 2004;75(3-4):253-60.
8. Pauly G., inventor Cosmetic, dermatological and pharmaceutical use of an extract of *Terminalia catappa*. USA patent 6217876. 2001.
9. Sirisa-Ard P., Chinprasoet N., Santiarworn D., Khruengkueanphet N., Phalasangram K., Kiatkaran S. Development of herbal tea from *Terminalia catappa* L. Leaves. The 6th Indochina Conference on and Pharmaceutical sciences; 2009; Hue, Vietnam. Hue college of Medicine

- Pharmacy; 2009. p. 102.
10. Chyau C-C., Tsai S-Y., Ko P-T., Mau J-L. Antioxidant properties of solvent extracts from *Terminalia catappa* leaves. *Food Chem.* 2002;78(4):483-8.
 11. Chyau C-C., Ko P-T., Mau J-L. Antioxidant properties of aqueous extracts from *Terminalia catappa* leaves. *LWT - Food Science and Technology.* 2006;39(10):1099-108.
 12. Khunamornpong S. Inflammation and repair. Faculty of Medicine, Chiang Mai University; 2009.
 13. Armstrong E., Klickstein L. Principle of inflammation and the immune system. 2 ed. USA: Wolters Kluwer; 2008.
 14. Cotran R., Kumar V., Collins T. Acute and chronic inflammation. USA: W.B. Saunders company; 1999.
 15. Gould BE. Pathophysiology for the health professions. 3 ed.: Philadelphia : Saunders Elsevier; 2006.
 16. Definition Pa. Cellular Mechanisms Involved in Airway Inflammation. National Institutes of Health; 1997.
 17. Halliwell B. Oxygen radicals, nitric oxide and human inflammatory joint disease. *Annals of the Rheumatic Diseases.* 1995;54:505-10.
 18. Kirby AJ., Schmidt RJ. The antioxidant activity of Chinese herbs for eczema and of placebo herbs I. *J Ethnopharmacol.* 1997;56:103-8.
 19. IARS. Fenton reaction. In: F2.large.jpg, editor. USA: International Anesthesia Research Society; 2010.
 20. Wutthamawech W. Hu-Kwang. Herb Encyclopedia. Bangkok: Odeon Store; 2540. p. 491.
 21. Dunstan CA., Noreen Y., Serrano G., Cox PA., Perera P., Bohlin L. Evaluation of some Samoan and Peruvian medicinal plants by prostaglandin biosynthesis and rat ear oedema assays. *J Ethnopharmacol.* 1997;57(1):35-56.
 22. Lin C-C., Hsu Y-F., Lin T-C., Hsu H-Y. Antioxidant and hepatoprotective effects of punicalagin and punicalin on acetaminophen-induced liver damage in rats. *Phytotherapy Research.* 2001;15(3):206-12.

23. *Terminalia catappa* Linn. (Combretaceae). Globinmed; 2010 [updated 2010; cited 2010 Dec 2010]; Available from:
http://www.globinmed.com/index.php?option=com_content&view=article&id=79155:terminalia-catappa-linn-combretaceae&catid=722:t.
24. Structure. National Center for Biotechnology Information, U.S. National Library of Medicine; 2012.
25. Lin C-C., Hsu Y-F., Lin T-C. Effects of punicalagin and punicalin on carrageenan-induced inflammation in rats. *Am J Chin Med.* 1999;27(3-4):371-6.
26. Adams LS., Seeram NP., Aggarwal BB., Takada Y., Sand D., Heber D. Pomegranate Juice, Total Pomegranate Ellagitannins, and Punicalagin Suppress Inflammatory Cell Signaling in Colon Cancer Cells. *J Agric Food Chem.* 2006;54(980-985).
27. Zhao L., Zhang S-L., Tao J-Y., Pang R., Jin F., Guo Y-J., et al. Preliminary exploration on anti-inflammatory mechanism of Corilagin (beta-1-O - galloyl-3, 6-(R)-hexahydroxydiphenoyl-D -glucose) *in vitro*. *International Immunopharmacol.* 2008;8:1059-64.
28. Povichit N., Phrutivorapongkul A., Suttajit M., Leelapornpisid P. Antiglycation and antioxidant activities of oxyresveratrol extracted from the heartwood of *Artocarpus lakoocha* Roxb. *Maejo Int J Sci Technol.* 2010;4(3):454-61.
29. Guoa Y-J., Zhaob L., Lic X-F., Meia Y-W., Zhangb S-L., Taod J-Y., et al. Effect of Corilagin on anti-inflammation in HSV-1 encephalitis and HSV-1 infected microglias. *European J Pharmacol.* . 2010; 635(1-3): 79-86
30. Shin SK., Chang JP., Doh ES. Studies on the effect of corilagin isolated from *Euphorbia helioscopia* on collagen-induced arthritis (II). *Korean J Plant Res.* 2008;21(4):336-40.
31. Lee S-I., Hyun P-M., Kim S-H., Kim K-S., Lee S-K., Kim B-S., et al. Suppression of the Onset and Progression of Collagen-Induced Arthritis by Chebulagic Acid Screened From a Natural Product Library. *Arthritis & Rheumatism.* 2005;52(1):345-53.

32. Chuysinuan P., Chimnoi N., Techasakul S., Supaphol P. Gallic acid-loaded electrospun poly(l-lactic acid) fiber mats and their release characteristic. *Macromol Chem Phys*. 2009;210:814-22.
33. Kim S-H., Jun C-D., Suk K., Choi B-J., Lim H., Park S., et al. Gallic Acid Inhibits Histamine Release and Pro-inflammatory Cytokine Production in Mast Cells. *Toxicol Sciences*. 2006;91(1):123-31.
34. Madlener S., Illmer C., Horvath Z., Saiko P., Losert A., Herbacek I., et al. Gallic acid inhibits ribonucleotide reductase and cyclooxygenases in human HL-60 promyelocytic leukemia cells. *Cancer Letters*. 2007;245(1-2):156-62.
35. Morikawa K., Nonaka M., Narahara M., Torii I., Kawaguchi K., Yoshikawa T., et al. Inhibitory effect of quercetin on carrageenan-induced inflammation in rats. *Life Sciences*. 2003;74(6):709-21.
36. Mahat MYA., Kulkarni NM., Vishwakarma SL., Khan FR., Thippeswamy BS., Hebballi V., et al. Modulation of the cyclooxygenase pathway via inhibition of nitric oxide production contributes to the anti-inflammatory activity of kaempferol. *Eur J Pharmacol.* . 2010; 642(1-3): 169-76.
37. Liu J., Li X., Yue Y., Li J., He T., He Y. The Inhibitory Effect of Quercetin on IL-6 Production by LPS Stimulated Neutrophils. *Cellular & Molecular Immunology*. 2005;2(6):455-60.
38. Subbaramaiah K., Michaluart P., Sporn MB., Dannenberg AJ. Ursolic Acid Inhibits Cyclooxygenase-2 Transcription in Human Mammary Epithelial Cells. *Cancer Res*. 2000;60:2399-404.
39. Kashfi K., Enna SJ., Michael W. Anti-Inflammatory Agents as Cancer Therapeutics. *Advances in Pharmacology*: Academic Press; 2009. p. 31-89.
40. Nair MP., Mahajan S., Reynolds JL., Aalinkeel R., Nair H., Schwartz SA., et al. The flavonoid quercetin inhibits proinflammatory cytokine (tumor necrosis factor alpha) gene expression in normal peripheral blood mononuclear cells via modulation of the NF-kappa beta system. *Clin Vaccine Immunol*. 2006;13(3):319-28.

41. Duke JA. Handbook of biologically active phytochemicals and their activities. Florida: CRC press; 1992.
42. Madlener S., Illmer C., Horvath Z., Saiko P., Losert A., Herbacek I., et al. Gallic acid inhibits ribonucleotide reductase and cyclooxygenases in human HL-60 promyelocytic leukemia cells. *Cancer Letters*. 2007;245:156–62.
43. United States Department of Agriculture; 2010. Dr. Duke's phytochemical and ethnobotanical databases: *Terminalia catappa*.
44. Ostrakhovitcha EA., Afanas'ev B. Oxidative stress in rheumatoid arthritis leukocytes: suppression by rutin and other antioxidants and chelators. *Biochemical Pharmacology*. 2001;62:743–6.
45. Pauly G., Nancy F., inventors; Pulnoy, FR, assignee. Cosmetic, dermatological and pharmaceutical use of an extract of *Terminalia catappa*. United States of America patent US6217876. 2001.
46. Renimel I., Olivier M., Andre P., inventors; Parfums Christian Dior, assignee. Use of an extract of the plant *Terminalia catappa* in the cosmetic and pharmaceutical fields, especially the dermatological field. USA patent 6413519. 2002.
47. Vajragupta O. Radical scavenging agents. Bangkok: P.S. Print; 2006.
48. Brattsand R., Thalen A., Roempke K., Kallstrom L., Gruvstad E. Influence of 16 alpha, 17 alpha-acetal substitution and steroid nucleus fluorination on the topical to systemic activity ratio of glucocorticoids. *J Steroid Biochem*. 1982;16(6):779-86.
49. Peerapornpisal Y., Amornlertpison D., Rujjanawate C., Ruangrita K., Kanjanapothi D. Two endemic species of macroalgae in Nan river. *Science Asia*. 2006;32:71-6.
50. Yata T. Anti-inflammatory activity of extract from *Caesalpinia mimosoides* Lamk. In press 2012.
51. Ritdecha K., Sutanthavibul N., Guideline of pharmaceutical development of semi-solid dosage form. Thai drug control division. Food and drug administration, Ministry of Public Health; 2003.

52. Rittirod T. Percutaneous absorption & transdermal drug delivery. Faculty of pharmaceutical sciences, Khon Kaen university; 2001.
53. Rotjanapan P., Kritsadapong P., Janyaprasert W., Satirakul K. Gel product development: Topical formulation and cosmetics. Bangkok: Faculty of Pharmacy, Mahidol University; 1994.
54. Bronuagh RL. *In vitro* percutaneous absorption models. In: Colors OoCa, editor. Maryland, USA: Food and Drug Administration. p. 188-91.
55. Skin picture. Japan: Kochi; 2009 [updated 2009; cited 1 Dec]; Available from: http://www.kachi.co.jp/SORCIERE/pic/picex_300.jpg.
56. Mahidol University. Faculty of Pharmacy. Specification of Thai Medicinal Plant. Bangkok: The University; 1986.
57. Drug Committee and the Food and Drug Administration of Thailand. Thai Pharmacopoeia 1987. Bangkok: Department of Medical Sciences, Ministry of Public Health; 1986.
58. Males Z., Medic-Saric M., Bucar F. Flavonoids of *Guiera senegalensis* J. F. GMEL. - thin-layer chromatography and numerical methods. *CCACAA*. 1998; 71(1) : 69-79.
59. Medic-Saric M., Jasprica I., Smolcic-Bubalo A., Mornar A. Optimization of chromatographic conditions in thin layer chromatography of flavonoids and phenolic acids. *CCACAA*. 2004; 77(1-2) : 361-66.
60. Brattsand R., Thalén A., Roempke K., Källström L., Gruvstad E. Development of new glucocorticosteroids with a very high ratio between topical and systemic activities. *European journal of respiratory diseases*. 1982; 122 : 62-73.
61. Javanmardi J., Stushnoff C., Locke E., Vivanco JM. Antioxidant activity and total phenolic content of Iranian *Ocimum accessions*. *Food Chemistry*. 2003; 83 : 547-50.
62. Bai X., Chen Y., Chen W., Lei H., Shi G. Volatile constituents, inorganic elements and primary screening of bioactivity of black coral cigarette holder. *Marines Drug*. 2011; 9 : 863-78.

63. Re R., Pellegrini N., Proteggente A., Pannala A., Yang M., Rice-Evans C. Antioxidant activity applying an improved ABTS radical cation decolorization assay. *Free Radical Biology & Medicine*. 1998;26:1231–7.
64. Nuño G., Zampini IC., Ordoñez RM., Alberto MR., Arias ME., Isla MI. Antioxidant/antibacterial activities of a topical phytopharmaceutical formulation containing a standardized extract of *Baccharis incarum*, an extremophile plant Species from Argentine puna. *Phytother Res*. 2012; 1 : 1-9.
65. Duke JA. *Terminalia catappa*. Handbook of Phytochemical Constituents of GRAS and Other Economic Plants. US: CRC Press; 1992. p. 591-2.
66. Pathan IB., Setty CM. Review article: Chemical penetration enhancers for transdermal drug delivery systems. *Tropical J Pharm Research*. 2009;8(2):173-9.
67. Neutralizing carbopol® and pemulen® polymers in aqueous and hydroalcoholic systems. Ohio: Noveon; 2002.